Nilesh Gupta, managing director of India's Lupin, told Bloomberg that his company gave Wockhardt a financial sizing up recently before deciding it didn't represent a good M&A target.
Pomona, CA-based PSC Investments has bought a 37,000-square-foot high-potency sterile injectable fill-finish facility from the Morgridge Institute for Research.
About an hour and a half west of Copenhagen is a little coastal town, Kalundborg, with 16,000 inhabitants, a famous five-steepled church and a castle dating back to at least the 14th century. It also happens to be the home of the plant that produces half of the world's insulin, the key component to most diabetes treatments.
Swiss-based CMO Lonza is cutting its tax liability here through the blessing of local economic development. It is not being required to return any of the tax incentives it got for a plant expansion after deciding to abandon a Massachusetts manufacturing site.
Fujifilm Diosynth Biotechnologies is adding a 2000-L single-use bioreactor at its plants in Research Triangle Park, NC, in the U.S. and Billingham in the U.K. to expand its cell culture manufacturing.
Sweden's Recipharm in April issued additional shares, preparing itself for expansion. Now the midsized contract and development group is putting those plans into play, buying an Italian company for more than $160 million, getting new business in Italy and emerging markets, as well as new capabilities.
GlaxoSmithKline's plan of action for its troubled Quebec flu vaccine has gotten the thumbs up from regulator Health Canada, but that is only a part of the puzzle for meeting its contracts to produce tens of millions of doses of four-strain and three-strain seasonal flu shots for the impending season.
Since the H1N1 pandemic scare revealed the shortcomings of U.S. production capacity when faced with an emergency, the Department of Health and Human Services (HHS) has invested in facilities to bolster defenses. With the death toll from Ebola now nearing 1,000, the plants are ready to switch to producing a drug or vaccine to protect people against the virus.
Alvogen has continued its expansion into Asia by striking a $187 million deal to acquire South Korean drugmaker Dream Pharma. And the acquisition will add another production plant to Alvogen's global network, with Dream Pharma's 368 employees and a facility in HyangNam coming under its control.
Having racked up several warning letters over the past few years, Fresenius Kabi is now optimistic that two of its affected plants are getting back on track. Further progress is dependent on FDA inspectors visiting the plants in Grand Island, NY, and Kalyani, India, but with the agency dealing with failings at multiple companies, Fresenius thinks it might be a while before the regulator visits.